Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older--United States, 2015
- PMID: 25654609
- PMCID: PMC4584856
Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older--United States, 2015
Abstract
In October 2014, the Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2015. This schedule provides a summary of ACIP recommendations for the use of vaccines routinely recommended for adults aged 19 years or older in two figures, footnotes for each vaccine, and a table that describes primary contraindications and precautions for commonly used vaccines for adults. Changes in the 2015 adult immunization schedule from the 2014 schedule included the August 2014 recommendation for routine administration of the 13-valent pneumococcal conjugate vaccine (PCV13) in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65 years or older, the August 2014 revision on contraindications and precautions for the live attenuated influenza vaccine (LAIV), and the October 2014 approval by the Food and Drug Administration to expand the approved age for use of recombinant influenza vaccine (RIV). These revisions were also reviewed and approved by the American College of Physicians, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and American College of Nurse-Midwives.
Similar articles
-
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017.MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):136-138. doi: 10.15585/mmwr.mm6605e2. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28182599 Free PMC article.
-
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.MMWR Recomm Rep. 2021 Aug 27;70(5):1-28. doi: 10.15585/mmwr.rr7005a1. MMWR Recomm Rep. 2021. PMID: 34448800 Free PMC article.
-
Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5. MMWR Morb Mortal Wkly Rep. 2014. PMID: 25233284 Free PMC article.
-
Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.Clin Ther. 2015 May 1;37(5):928-34. doi: 10.1016/j.clinthera.2015.03.025. Epub 2015 Apr 23. Clin Ther. 2015. PMID: 25913921 Review.
-
Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?Can Fam Physician. 2019 Sep;65(9):625-633. Can Fam Physician. 2019. PMID: 31515311 Free PMC article. Review.
Cited by
-
Current perspective on infections and mitigation strategies in primary systemic vasculitis.Curr Rheumatol Rep. 2024 Aug;26(8):279-289. doi: 10.1007/s11926-024-01149-6. Epub 2024 Apr 26. Curr Rheumatol Rep. 2024. PMID: 38668813 Review.
-
MAURIVAX: A Vaccination Campaign Project in a Hospital Environment for Patients Affected by Autoimmune Diseases and Adult Primary Immunodeficiencies.Vaccines (Basel). 2023 Oct 11;11(10):1579. doi: 10.3390/vaccines11101579. Vaccines (Basel). 2023. PMID: 37896982 Free PMC article.
-
Attitude, Familiarity and Religious Beliefs about Vaccination among Health Science and Non-Health Science Students in a Malaysian Public University.Eur J Investig Health Psychol Educ. 2021 Nov 18;11(4):1462-1473. doi: 10.3390/ejihpe11040104. Eur J Investig Health Psychol Educ. 2021. PMID: 34842641 Free PMC article.
-
Opsonization-Enhanced Antigen Presentation by MR1 Activates Rapid Polyfunctional MAIT Cell Responses Acting as an Effector Arm of Humoral Antibacterial Immunity.J Immunol. 2020 Jul 1;205(1):67-77. doi: 10.4049/jimmunol.2000003. Epub 2020 May 20. J Immunol. 2020. PMID: 32434941 Free PMC article. Clinical Trial.
-
Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease.Hum Vaccin Immunother. 2021 Jan 2;17(1):162-169. doi: 10.1080/21645515.2020.1756669. Epub 2020 May 19. Hum Vaccin Immunother. 2021. PMID: 32429734 Free PMC article.
References
-
- Tomcsyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2014;63:822–5. - PMC - PubMed
-
- Food and Drug Administration. October 29, 2014 approval letter—Flublok. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm4....
-
- Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2015. Ann Intern Med. 2015;162:214–23. - PubMed
